Avid Initiates First Phase II Alzheimer's Disease Trial
Posted on: Tuesday, 10 June 2008, 09:01 CDT
Avid Radiopharmaceuticals has initiated a Phase II clinical trial studying 18F-AV-45, an investigational molecular imaging compound under development for imaging Alzheimer's disease.
Avid's 18F-AV-45 is used with positron emission tomography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer's disease.
This US Phase II clinical trial of 18F-AV-45 will enroll approximately 200 patients with varying degrees of memory loss at more than 30 centers across the country. The trial involves a single administration of 18F-AV-45 and a PET imaging procedure that is completed in less than one hour.
The study is designed to show how 18F-AV-45 imaging of amyloid plaque compares between healthy volunteers, patients with mild cognitive impairment, and patients with Alzheimer's disease. This initial Phase II study is reportedly the first of several trials planned to study the effectiveness of this Avid molecular imaging agent in more than 500 patients worldwide.
This is also reportedly the first large-scale multi-center trial of an 18F-labeled PET molecular imaging agent for visualizing amyloid plaques.
Daniel Skovronsky, president and CEO of Avid, said: "The initiation of this study is a major milestone for Avid and what will be a major advance for the field of molecular imaging."
Source: Datamonitor
Related Articles
- Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
- Merge OEM Software Used in New Study for Alzheimer's
- Prana Announces Success in Phase IIa Clinical Trial of PBT2 in Early Alzheimer's Disease
- Prana Completes Final Patient Dosing in Alzheimer's Phase II Trial
- Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
- Cortex to Resume Clinical Trial With AMPAKINE(R) CX717 in Alzheimer-PET Scan Study After FDA Approves Protocol With Higher Doses of Drug
- EPIX Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients With Mild Alzheimer's Disease
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- Patients With Mild Alzheimer's Capable of Treatment Decisions
 |
 |
User Comments (0)
RSS Feeds